CD99 and neoplasm: In general, data obtained in both EWS and leukemia (Husak et al. 2010) indicate that CD99-induced cell death occurs preferentially in cells with an aberrant genetic background, thus conferring selectivity of anti-CD99 approaches against tumor cells.